Angiogenesis Modulating Agents
- Name
- Angiogenesis Modulating Agents
- Accession Number
- DBCAT000213
- Description
Agents that modulate the PHYSIOLOGIC ANGIOGENESIS process. This is accomplished by endogenous ANGIOGENIC PROTEINS and a variety of other chemicals and pharmaceutical agents.
- Drugs
Drug Drug Description Bevacizumab A monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer. Lenalidomide A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome. Ranibizumab A recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema. Pomalidomide A thalidomide analogue used in combination with dexamethasone to treat patients with multiple myeloma. Becaplermin A recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area. Thalidomide A medication used to treat cancers, particularly newly diagnosed multiple myeloma, and erythema nodosum leprosum. Sunitinib A receptor tyrosine kinase inhibitor and chemotherapeutic agent used for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). Fumagillin Not Available Halofuginone For the treatment of scleroderma, cancer, and restenosis. Tetrathiomolybdate Investigated for use/treatment in liver disease and pulmonary fibrosis. Oglufanide Investigated for use/treatment in hepatitis (viral, C). Endostatin Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy. Semaxanib Investigated for use/treatment in colorectal cancer and lung cancer. Squalamine Investigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration. Volociximab Investigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. TNP-470 O-(chloroacetylcarbamoyl)fumagillol (TNP-470) has been used in trials studying the treatment of HIV Infections, Sarcoma, Kaposi, and Pancreatic Neoplasms. Aflibercept A vascular endothelial growth factor (VEGF) inhibitor used to treat Neovascular (Wet) Age-Related Macular Degeneration (AMD), various types of macular edema and diabetic retinopathy. Roquinimex Roquinimex is investigated to be used as a treatment of a number of cancers and autoimmune conditions. As well, roquinimex is researched to be used as adjuvant therapy after bone... Endostar Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. Trebananib Trebananib is under investigation for the treatment of Ovarian Cancer, Peritoneal Cancer, and Fallopian Tube Cancer. Trebananib has been investigated for the treatment of Cancer, Oncology, Carcinoma, Metastases, and Colon... Anecortave Anecortave is under investigation in clinical trial NCT00691717 (Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension). Beloranib Beloranib has been used in trials studying the treatment of Obesity, Over-weight, Type 2 Diabetes, Craniopharyngioma, and Hypothalamic Injury, among others. Xanthohumol Xanthohumol is under investigation in clinical trial NCT01367431 (Xanthohumol and Metabolic Syndrome). Edodekin alfa Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or... - Drugs & Drug Targets